StocksFundsScreenerSectorsWatchlists
CORT

CORT - Corcept Therapeutics Inc Stock Price, Fair Value and News

25.48USD+0.16 (+0.63%)Delayed as of 28 Mar 2024, 01:03 pm ET

Market Summary

CORT
USD25.48+0.16
Delayedas of 28 Mar 2024, 01:03 pm
0.63%

CORT Alerts

  • 1 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

CORT Stock Price

View Fullscreen

CORT RSI Chart

CORT Valuation

Market Cap

2.6B

Price/Earnings (Trailing)

24.69

Price/Sales (Trailing)

5.43

EV/EBITDA

19.86

Price/Free Cashflow

20.65

CORT Price/Sales (Trailing)

CORT Profitability

Operating Margin

99.72%

EBT Margin

25.82%

Return on Equity

20.95%

Return on Assets

17.08%

Free Cashflow Yield

4.84%

CORT Fundamentals

CORT Revenue

Revenue (TTM)

482.4M

Rev. Growth (Yr)

31.39%

Rev. Growth (Qtr)

9.55%

CORT Earnings

Earnings (TTM)

106.1M

Earnings Growth (Yr)

88.87%

Earnings Growth (Qtr)

-0.07%

Breaking Down CORT Revenue

52 Week Range

21.0034.28
(Low)(High)

Last 7 days

5.5%

Last 30 days

7.9%

Last 90 days

-25.2%

Trailing 12 Months

12.2%

How does CORT drawdown profile look like?

CORT Financial Health

Current Ratio

4.39

CORT Investor Care

Buy Backs (1Y)

4.00%

Diluted EPS (TTM)

0.95

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023413.8M428.2M450.0M482.4M
2022380.2M392.0M397.6M401.9M
2021340.1M343.1M352.9M366.0M
2020334.9M351.2M356.0M353.9M
2019258.4M268.4M285.4M306.5M
2018189.3M216.0M237.7M251.2M
201792.9M108.7M129.7M159.2M
201656.2M64.0M72.5M81.3M
201532.2M38.4M44.3M50.3M
201413.0M17.0M21.7M26.6M
20135.0M6.0M7.6M10.4M
20122.4M2.7M3.0M3.3M
2011001.8M2.1M
20100566.0K1.0M1.5M
2009000101.0K

Tracking the Latest Insider Buys and Sells of Corcept Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 19, 2024
maduck sean
acquired
26,100
2.61
10,000
see remarks
Mar 18, 2024
maduck sean
sold
-430,475
25.00
-17,219
see remarks
Mar 18, 2024
maduck sean
acquired
66,809
3.88
17,219
see remarks
Mar 01, 2024
maduck sean
sold (taxes)
-12,150
24.06
-505
see remarks
Mar 01, 2024
swisher daniel n jr
acquired
12,892
5.86
2,200
-
Mar 01, 2024
lyon joseph douglas
sold (taxes)
-11,404
24.06
-474
chief accounting officer
Mar 01, 2024
robb gary charles
sold (taxes)
-15,783
24.06
-656
chief business officer
Mar 01, 2024
mokari atabak
acquired
13,329
12.03
1,108
chief financial officer
Mar 01, 2024
guyer william
sold (taxes)
-14,532
24.06
-604
chief development officer
Mar 01, 2024
robb gary charles
acquired
16,769
12.03
1,394
chief business officer

1–10 of 50

Which funds bought or sold CORT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
added
28.36
123,887
357,540
-%
Mar 11, 2024
VANGUARD GROUP INC
added
2.58
56,464,700
309,779,000
0.01%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
160
23,476,500
34,608,100
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.88
220,395
1,433,340
0.01%
Feb 26, 2024
Virtu Financial LLC
sold off
-100
-227,000
-
-%
Feb 26, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
161,000
1,005,000
0.01%
Feb 26, 2024
SYON CAPITAL LLC
new
-
204,851
204,851
0.02%
Feb 26, 2024
Neo Ivy Capital Management
sold off
-100
-66,000
-
-%
Feb 23, 2024
CIM, LLC
new
-
359,794
359,794
0.06%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
5.85
347,000
1,674,000
-%

1–10 of 44

Are Funds Buying or Selling CORT?

Are funds buying CORT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CORT
No. of Funds

Unveiling Corcept Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
baker g leonard jr
5.3%
5,512,696
SC 13G/A
Feb 13, 2024
renaissance technologies llc
6.52%
6,725,871
SC 13G/A
Feb 13, 2024
vanguard group inc
9.25%
9,537,532
SC 13G/A
Feb 12, 2024
belanoff joseph k
6.1%
6,581,918
SC 13G/A
Jan 22, 2024
blackrock inc.
15.9%
16,407,696
SC 13G/A
Feb 17, 2023
ingalls & snyder llc
6.6%
7,090,370
SC 13G/A
Feb 15, 2023
belanoff joseph k
5.5%
6,081,918
SC 13G/A
Feb 14, 2023
baker g leonard jr
5.1%
5,485,196
SC 13G/A
Feb 13, 2023
renaissance technologies llc
6.77%
7,288,871
SC 13G/A
Feb 09, 2023
vanguard group inc
9.61%
10,345,030
SC 13G/A

Recent SEC filings of Corcept Therapeutics Inc

View All Filings
Date Filed Form Type Document
Mar 27, 2024
144
Notice of Insider Sale Intent
Mar 27, 2024
SC 13G/A
Major Ownership Report
Mar 20, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 01, 2024
144
Notice of Insider Sale Intent

What is the Fair Value of CORT?

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Cheap
or
Expensive?


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks

Peers (Alternatives to Corcept Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

Corcept Therapeutics Inc News

Latest updates
InvestorsObserver • 81 minutes ago
Investing.com • 20 Mar 2024 • 10:11 pm
CNN • 2 months ago

Corcept Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue9.6%13512411810610310210394.0099.0096.0092.0079.0086.0086.0089.0093.0088.0082.0072.0065.0067.00
Costs and Expenses12.2%10492.0088.0091.0081.0070.0072.0067.0062.0060.0060.0060.0055.0062.0053.0056.0053.0049.0048.0046.0042.00
  S&GA Expenses4.2%47.0045.0043.0049.0042.0035.0038.0038.0032.0031.0030.0030.0026.0027.0026.0028.0027.0024.0025.0024.0022.00
  R&D Expenses20.2%55.0046.0043.0041.0037.0033.0033.0028.0029.0028.0028.0029.0028.0034.0026.0026.0024.0023.0022.0020.0019.00
EBITDA Margin3.6%0.26*0.25*0.26*0.26*0.29*0.33*0.33*0.35*0.34*0.34*0.32*0.33*---------
Income Taxes9.2%5.005.005.003.008.00-1.605.004.005.006.006.00-3.605.004.008.009.007.008.006.002.004.00
Earnings Before Taxes1.2%37.0036.0033.0018.0024.0033.0032.0027.0037.0036.0032.0020.0031.0025.0036.0039.0036.0034.0026.0020.0026.00
EBT Margin3.7%0.26*0.25*0.25*0.26*0.29*0.32*0.34*0.35*0.34*0.34*0.32*0.33*---------
Net Income-0.1%31.0031.0028.0016.0017.0035.0027.0023.0032.0030.0027.0023.0026.0022.0028.0030.0029.0026.0020.0018.0022.00
Net Income Margin8.4%0.22*0.20*0.22*0.23*0.25*0.29*0.29*0.29*0.31*0.30*0.28*0.29*---------
Free Cashflow-88.9%6.0053.0042.0026.0033.0033.0018.0035.0049.0049.0044.0025.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets4.6%622594525618583533496468424585568552572534498445412367329320312
  Current Assets6.3%459432433534499452419388266402411410479463438345307267233217237
    Cash Equivalents21.2%13611217230066.0050.0035.0062.0078.0095.0095.0052.0076.0031.0059.0084.0031.0045.0058.0050.0042.00
  Inventory2.9%8.008.007.006.006.006.005.005.005.005.005.005.005.005.005.005.005.005.005.005.005.00
  Net PPE-35.4%0.000.000.000.001.001.001.001.001.001.001.001.002.001.001.001.001.001.001.001.001.00
Liabilities-13.2%11513210388.0082.0060.0054.0060.0048.0045.0046.0042.0048.0044.0044.0036.0041.0033.0031.0034.0036.00
  Current Liabilities-14.3%10512293.0079.0072.0053.0049.0057.0048.0045.0045.0041.0047.0043.0042.0034.0039.0032.0030.0034.0036.00
Shareholder's Equity9.8%507462422530502473442408376540523511523490454409371334298286276
  Retained Earnings8.4%40337134031229628024521819516313210682.0056.0035.007.00-23.55-52.94-79.28-99.46-117
  Additional Paid-In Capital2.2%739722696680662649626609591571554536516496482466457447437427417
Shares Outstanding-0.5%103104105108108107106106116116117117---------
Float---1,827---2,058---2,122---1,633---1,071--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-88.9%5,88752,90942,28625,95733,38833,64818,04035,24749,42748,70444,33925,42235,07130,44453,18633,26948,45438,42725,55523,68121,519
  Share Based Compensation1.5%13,06512,87611,85811,14110,52110,55410,60610,76110,81010,95211,06810,1018,4308,7028,4897,9187,6107,2717,7366,6966,266
Cashflow From Investing115.6%17,098-109,570-24,097207,475-17,241-4,790-41,800-50,496140,471-25,80324,742-3,28411,220-64,273-85,94419,734-61,989-54,316-1,156-367-1,757
Cashflow From Financing119.6%766-3,916-145,754181-61.00-13,961-2,756-506-206,969-23,643-26,032-45,947-6615,8666,804205-1442,696-15,908-15,289-12,031
  Buy Backs----------25,77429,17033,5419,670--275--17,42013,55514,753

CORT Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Product revenue, net$ 482,375$ 401,858$ 365,978
Operating expenses:   
Cost of sales6,4815,3855,281
Research and development184,353130,991113,864
Selling, general and administrative184,259152,848122,356
Settlement expense related to Melucci litigation014,0000
Insurance recovery related to Melucci litigation0(14,000)0
Total operating expenses375,093289,224241,501
Income from operations107,282112,634124,477
Interest and other income17,2753,557529
Income before income taxes124,557116,191125,006
Income tax expense(18,417)(14,773)(12,494)
Net income106,140101,418112,512
Net income attributable to common stockholders, basic105,496101,288112,512
Net income attributable to common stockholders, diluted$ 105,496$ 101,288$ 112,512
Basic net income per share (in dollars per share)$ 1.02$ 0.95$ 0.97
Diluted net income per share (in dollars per share)$ 0.94$ 0.87$ 0.89
Weighted-average shares outstanding used in computing net income per common share   
Basic (in shares)103,560106,787115,653
Diluted (in shares)111,742115,966125,963

CORT Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 135,551$ 66,329
Short-term marketable securities232,670365,343
Trade receivables, net of allowances41,12331,057
Insurance recovery receivable related to Melucci litigation (Note 10)14,00014,000
Inventory7,7306,100
Prepaid expenses and other current assets27,56216,424
Total current assets458,636499,253
Strategic inventory8,24410,931
Operating lease right-of-use asset1201,143
Property and equipment, net of accumulated depreciation and amortization195633
Long-term marketable securities57,1764,947
Other assets6,5415,058
Deferred tax assets, net90,60561,465
Total assets621,517583,430
Current liabilities:  
Accounts payable17,39611,976
Accrued research and development expenses21,33014,573
Accrued and other liabilities51,62830,799
Accrued settlement related to Melucci litigation (Note 10)14,00014,000
Short-term operating lease liability1511,143
Total current liabilities104,50572,491
Long-term accrued income taxes payable10,3079,097
Total liabilities114,81281,588
Commitments and contingencies (Note 10)
Stockholders’ equity:  
Preferred stock, par value $0.001 per share, 10,000 shares authorized and no shares outstanding as of December 31, 2023 and December 31, 202200
Common stock, par value $0.001 per share, 280,000 shares authorized and 134,344 issued and 103,405 outstanding as of December 31, 2023 and 130,959 shares issued and 107,835 outstanding as of December 31, 2022133131
Treasury stock; at cost; 30,938 shares of common stock as of December 31, 2023 and 23,124 shares of common stock as of December 31, 2022(635,078)(456,148)
Additional paid-in capital738,515662,342
Accumulated other comprehensive income (loss)609(869)
Retained earnings402,526296,386
Total stockholders’ equity506,705501,842
Total liabilities and stockholders’ equity$ 621,517$ 583,430
CORT
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
 CEO
 WEBSITEwww.corcept.com
 EMPLOYEES299

Corcept Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Corcept Therapeutics Inc? What does CORT stand for in stocks?

CORT is the stock ticker symbol of Corcept Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Corcept Therapeutics Inc (CORT)?

As of Wed Mar 27 2024, market cap of Corcept Therapeutics Inc is 2.62 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CORT stock?

You can check CORT's fair value in chart for subscribers.

What is the fair value of CORT stock?

You can check CORT's fair value in chart for subscribers. The fair value of Corcept Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Corcept Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CORT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Corcept Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CORT is over valued or under valued. Whether Corcept Therapeutics Inc is cheap or expensive depends on the assumptions which impact Corcept Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CORT.

What is Corcept Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, CORT's PE ratio (Price to Earnings) is 24.69 and Price to Sales (PS) ratio is 5.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CORT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Corcept Therapeutics Inc's stock?

In the past 10 years, Corcept Therapeutics Inc has provided 0.195 (multiply by 100 for percentage) rate of return.